静脈血栓塞栓症(VTE)治療の世界市場2017-2021...市場調査レポートについてご紹介

【英文タイトル】Global Venous Thromboembolism Therapeutics Market 2017-2021

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

PART 01: Executive summary

PART 02: Scope of  the report

Market overview
Top-vendor offerings

PART 03: Market research methodology

Research methodology
Economic indicators

PART 04: Introduction

Key market highlights
Highlights

PART 05: Disease overview

Diagnosis of VTE
Treatment of VTE

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview
Five forces analysis

PART 08: Market segmentation by drug class

Factor Xa inhibitors
Direct thrombin inhibitors
Heparin
Vitamin K antagonists

PART 09: Geographical segmentation

VTE therapeutics market in Americas
VTE therapeutics market in EMEA
VTE therapeutics market in APAC

PART 10: Market drivers

Increasing adoption of NOACs
Increasing surgical procedures such as hip and knee replacements
Large patient pool coupled with growing awareness campaigns

PART 11: Impact of drivers

PART 12: Market challenges

Presence of alternatives such as thrombectomy and percutaneous techniques
Unmet needs for anticoagulant reversal agents
Extensive use of generic products

PART 13: Impact of drivers and challenges

PART 14: Market trends

Development of drugs for new indications
Growing focus on emerging economies
Patient assistance programs

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Bayer HealthCare
BMS
Boehringer Ingelheim
Daiichi Sankyo
Johnson & Johnson
Sanofi
Other prominent vendors

PART 17: Appendix

List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings

Exhibit 02: Types of venous thromboembolism

Exhibit 03: Pipeline analysis

Exhibit 04: Key pipeline molecules

Exhibit 05: Global VTE therapeutics market snapshot

Exhibit 06: Global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 07: Opportunity analysis in global venous thromboembolism market

Exhibit 08: Five forces analysis

Exhibit 09: Factor Xa inhibitors in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 10: Direct thrombin inhibitors in venous thromboembolism market 2016-2021 ($ millions)

Exhibit 11: Heparin in global VTE therapeutics market 2016-2021 ($ millions)

Exhibit 12: Vitamin K antagonists in global venous thromboembolism market 2016-2021 ($ millions)

Exhibit 13: Segmentation of global VTE therapeutics market based on geography 2016 and 2021

Exhibit 14: VTE therapeutics market revenue by geography 2016-2021 (%)

Exhibit 15: Market scenario in Americas

Exhibit 16: VTE therapeutics market in Americas 2016-2021 ($ millions)

Exhibit 17: Market scenario in EMEA

Exhibit 18: VTE therapeutics market in EMEA ($ millions)

Exhibit 19: Market scenario in APAC

Exhibit 20: Venous thromboembolism therapeutics market in APAC ($ millions)

Exhibit 21: Impact of drivers

Exhibit 22: Forcefield analysis of drivers and challenges

Exhibit 23: Impact of drivers and challenges

Exhibit 24: Competitive structure analysis of global VTE therapeutics market 2015

Exhibit 25: Competitive analysis of global VTE therapeutics market 2016

Exhibit 26: Market share analysis 2015

Exhibit 27: Market penetration of various VTE manufacturers worldwide 2016

Exhibit 28: Strategic success factors of companies in global VTE therapeutics market

Exhibit 29: Bayer HealthCare: Key highlights

Exhibit 30: Bayer HealthCare: Strength assessment

Exhibit 31: Bayer HealthCare: Strategy assessment

Exhibit 32: Bayer HealthCare: Opportunity assessment

Exhibit 33: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2013-2015 ($ billions)

Exhibit 34: BMS: Key highlights

Exhibit 35: BMS: Strength assessment

Exhibit 36: BMS: Strategy assessment

Exhibit 37: BMS: Opportunity assessment

Exhibit 38: BMS: YoY revenue and growth rate of Eliquis (outside the US) 2013-2015 ($ millions)

Exhibit 39: Geographic segmentation of Eliquis 2015

Exhibit 40: Boehringer Ingelheim: Key highlights

Exhibit 41: Boehringer Ingelheim: Strength assessment

Exhibit 42: Boehringer Ingelheim: Strategy assessment

Exhibit 43: Boehringer Ingelheim: Opportunity assessment

Exhibit 44: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (Global) 2013-2015 ($ billions)

Exhibit 45: Daiichi Sankyo: Key highlights

Exhibit 46: Daiichi Sankyo: Strength assessment

Exhibit 47: Daiichi Sankyo: Strategy assessment

Exhibit 48: Daiichi Sankyo: Opportunity assessment

Exhibit 49: Johnson & Johnson: Key highlights

Exhibit 50: Johnson & Johnson: Strength assessment

Exhibit 51: Johnson & Johnson: Strategy assessment

Exhibit 52: Johnson & Johnson: Opportunity assessment

Exhibit 53: Johnson & Johnson: YoY revenue and growth rate of Xarelto 2013-2015 ($ millions)

Exhibit 54: Sanofi: Key highlights

Exhibit 55: Sanofi: Strength assessment

Exhibit 56: Sanofi: Strategy assessment

Exhibit 57: Sanofi: Opportunity assessment

Exhibit 58: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)

Exhibit 59: Geographical segmentation of Lovenox 2015


【レポート販売概要】

■ タイトル:静脈血栓塞栓症(VTE)治療の世界市場2017-2021
■ 英文:Global Venous Thromboembolism Therapeutics Market 2017-2021
■ 発行日:2017年2月17日
■ 調査会社:Technavio
■ 商品コード:IRTNTR12030
■ 調査対象地域:世界
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。